Non-operative management

PROCEDURE7 trials

Sponsors

DFINE Inc., Mount Sinai Hospital, Canada, University of Missouri-Columbia, Jules Bordet Institute, The Cleveland Clinic

Conditions

AK112AppendicitisCholecystitisCholecystitis, AcuteCholecystitis; GallstoneColorectal CancerCovid19Metacarpal Fracture

Phase 2

Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer

Active, not recruitingNCT04503694

Jules Bordet InstituteRectal Cancer Stage II, Rectal Cancer Stage III

Start: 2021-03-25End: 2032-12-01Target: 72Updated: 2026-05-22

Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer

RecruitingNCT06903858

Sun Yat-sen UniversityColorectal Cancer, Microsatellite Instability High, Mismatch Repair Deficiency

Start: 2025-06-01End: 2031-04-01Target: 105Updated: 2026-05-22

SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer

Not yet recruitingNCT07162714

Zhejiang Cancer HospitalAK112, Radiation, Rectal Cancer

Start: 2025-09-01End: 2028-12-31Target: 30Updated: 2025-09-09

Phase 4

The PRIORi-T Trial--Prospective Randomized Investigation of Radiofrequency Targeted Vertebral Augmentation

WithdrawnNCT01480167

DFINE Inc.Painful Osteoporotic Vertebral Compression Fractures (VCF)

Start: 2011-11-30Updated: 2017-01-20

Unknown Phase

Non-operative Management for Locally Advanced Rectal Cancer

RecruitingNCT03179540

Mount Sinai Hospital, CanadaRectal Neoplasms

Start: 2018-03-16End: 2026-12-31Target: 90Updated: 2024-11-20

Non-operative vs Surgical Treatment of Isolated Non-Thumb Metacarpal Shaft Fractures

TerminatedNCT04001062

University of Missouri-ColumbiaMetacarpal Fracture

Start: 2019-06-12End: 2022-04-15Updated: 2023-06-29

Operative vs Non-Operative Management of Acute Appendicitis and Acute Cholecystitis in COVID-19 Positive Patients

TerminatedNCT04748120

The Cleveland ClinicAppendicitis, Cholecystitis, Cholecystitis, Acute +2

Start: 2020-12-28End: 2021-04-06Updated: 2022-03-14

Related Papers

REGINA: A phase II trial of neoadjuvant regorafenib (Rego) in combination with nivolumab (Nivo) and short-course radiotherapy (SCRT) in intermediate-risk, stage II-III rectal cancer (RC).

Journal of Clinical Oncology2022-01-193 citations